SCHEMBL3906317

SCHEMBL3906317

CN(Cc1ccc(F)cc1F)C(=O)c1ccc(Cl)cc1NS(=O)(=O)C1=CC=CN2SNC=C12

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 10/20 0.39
CCKBR P32239 2/20 0.38
CCKAR P32238 1/20 0.34
HAO1 Q9UJM8 1/20 0.34
KMT2A Q03164 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPK1 P28482 1/20 0.33
MEN1 O00255 1/20 0.33
RIPK1 Q13546 1/20 0.33
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32
LMNA P02545 1/20 0.30
TP53 P04637 1/20 0.30
MAPT P10636 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3902440 0.95 CCKBR (0.38) CCR2CCKBRCCKARHAO1KMT2A
SCHEMBL3915008 0.94 CCR2 (0.37) CCR2CCKBRHAO1KMT2AALDH1A1
SCHEMBL3899767 0.92 KMT2A (0.35) KMT2AMEN1RIPK1MAPT
SCHEMBL3900463 0.91 MEN1 (0.33) CCKBRKMT2AMEN1RIPK1
SCHEMBL3895762 0.91 MEN1 (0.33) KMT2AMEN1RIPK1
SCHEMBL3900438 0.91 CCKBR (0.44) CCR2CCKBRCCKARKMT2ALMNA
SCHEMBL3901168 0.91 CRHBP (0.40) CCR2CCKBRCCKARKMT2AALDH1A1
SCHEMBL3907650 0.90 KMT2A (0.39) KMT2AALDH1A1MEN1RIPK1MAPT
SCHEMBL3902433 0.89 CRHBP (0.36) CCR2CCKBRHAO1KMT2AALDH1A1
SCHEMBL3907638 0.88 KMT2A (0.34) CCR2CCKBRHAO1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7241759-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-10 US claimed
US-7550492-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-23 US disclosed
US-20070276016-A1 BENZO[1,2,5]THIADIAZOLE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-29 US disclosed
US-7241759-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-10 US disclosed
EP-1675837-A2 BENZO [1,2,5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-05 EP disclosed
WO-2005012275-A2 BENZO [1, 2, 5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-10 WO disclosed
US-20040224983-A1 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276016-A1 BENZO[1,2,5]THIADIAZOLE COMPOUNDS CCKBR, CCKAR, GIPR CCR2 478/4885CCKBR 1/4885CCKAR 2/4885
US-20040224983-A1 Benzo[1,2,5]thiadiazole compounds CCKBR, CCKAR, BRSK2 CCR2 1079/4885CCKBR 1/4885CCKAR 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.